Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDDS II: Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep
NCT06192615Phase 3Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in delirium (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Delirium. Started Jan 2025; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
delirium
Beyond the preview
Go deeper on NCT06192615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192615.